VCM
AXSM icon

Virtue Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Virtue Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,807
Closed -$711K – 300
2025
Q2 		$711K Sell
6,807
-738
-10% -$78.1K 0.13% 115
2025
Q1 		$882K Buy
+7,545
New +$860K 0.1% 161

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtue Capital Management's AXSM Position: Q3 2025 in Review

Virtue Capital Management sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 6,807 shares — an estimated $711K sold.

Virtue Capital Management first reported a position in AXSM in Q1 2025 and held it in 2 quarters. The position peaked at $882K in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Virtue Capital Management reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Virtue Capital Management sold 6,807 Axsome Therapeutics shares in Q3 2025, an estimated $711K.
  • Virtue Capital Management first reported a position in Axsome Therapeutics in Q1 2025 and held it in 2 quarters.
  • Virtue Capital Management's Axsome Therapeutics position peaked at $882K in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Virtue Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.